Interventional Glaucoma

All 696 patients in the trial have completed their treatment and follow-up visits.

Perfuse Therapeutics is conducting trials for the treatment for glaucoma and diabetic retinopathy, aiming to restore vision and combat global blindness.

From Nobel laureates to AI-driven research, the Wilmer Eye Institute honors a century of transforming vision science and care.

Qlaris Bio to showcase promising data on QLS-111, a novel glaucoma treatment, at the 2025 World Glaucoma Congress, highlighting its efficacy and safety.

Perfuse Therapeutics reveals promising Phase 2 trial results for PER-001, a potential treatment for glaucoma and diabetic retinopathy.

Funding will support the continued clinical advancement of its lead ocular implant candidate, PA5108, for the reduction of IOP in patients with ocular hypertension and glaucoma.

EssilorLuxottica and MidEuropa recently entered into an agreement that will allow EssilorLuxottica to acquire Optegra, building upon its med-tech strategy.

The novel preservative-free eye drop therapy for glaucoma aims to improve IOP control and patient adherence with a fixed-dose combination.

Weighing the benefits and trade-offs of preserved versus preservative-free glaucoma treatments is key to optimizing long-term patient care.

SpyGlass Pharma secures $75 million in Series D funding to enhance its innovative drug delivery platform for long-term glaucoma management.

This partnership aims to address care gaps by identifying untreated and undertreated patients at scale.

The investigators described the CASIA2 (Tomey Corporation) instrument, which is a new AS-OCT device with a swept-source laser wavelength of 1,310 nm that can scan at a speed of 50,000 A-scan/second.

Swedish researchers reveal that vitamins B6, B9, B12, and choline offer neuroprotection against glaucoma, highlighting potential new treatment avenues.

NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop with a dual mechanism of action (nitric oxide and prostaglandin analogue).

Perfuse Therapeutics reveals promising results for PER-001, a groundbreaking glaucoma treatment, enhancing vision and ocular health in clinical trials.

STAR-GLOBAL is an extension trial of the initial EU clinical trials investigating the long term safety and efficacy of MINIject in patients with glaucoma with up to 5 years of follow up.

Leos is supported by emerging data from a randomized controlled clinical trial, further validating its safety and efficacy.

A survey collected demographic data, ocular and medical history, and responses assessing knowledge of glaucoma and cataracts in the Qassim region of Saudi Arabia.

Tapcom is a preservative-free, fixed-combination eye drop of tafluprost 0.0015% and timolol 0.5% for lowering intraocular pressure.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

The trial is designed to assess the safety and effectiveness of Avisi Technologies' investigational VisiPlate device in patients with open-angle glaucoma.

The May 4 event, themed around Star Wars, will feature the latest innovations, foster open discussions, and provide a collaborative environment for networking and learning, with sessions covering IOLs, oculoplastics, glaucoma, retina therapy, and refractive surgical options.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

A combination of canaloplasty and goniotomy provides sustained IOP reduction and decreases medication burden with a strong safety profile, making it a valuable option for glaucoma management.

An AI model for target IOP prediction performs as well as glaucoma specialists, offering a promising tool to enhance glaucoma management, especially for nonspecialists.

ZEISS VISULAS Combi is an advanced therapeutic laser workstation offering photodisruption, photocoagulation, and slit lamp technology in a single, comprehensive solution.

The novel nitric oxide-donating bimatoprost eye drop is being clinically developed for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.

The 9 recipients receive $55,000 in seed money for collaborative projects that target one or more of the foundation’s strategic research goals.